Cabozantinib is a tyrosine kinase inhibitor, known for inhibiting VEGFR, MET, and AXL, already in clinical use against multiple kinds of malignancies like hepatocellular carcinoma (71), sarcoma (72), and renal-cell carcinoma (73). This evidence concerns the gene AXL and hepatocellular carcinoma.